Cargando…

CAR Macrophages for SARS-CoV-2 Immunotherapy

Targeted therapeutics for the treatment of coronavirus disease 2019 (COVID-19), especially severe cases, are currently lacking. As macrophages have unique effector functions as a first-line defense against invading pathogens, we genetically armed human macrophages with chimeric antigen receptors (CA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Wenyan, Lei, Changhai, Ma, Zetong, Qian, Kewen, Li, Tian, Zhao, Jian, Hu, Shi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343226/ https://www.ncbi.nlm.nih.gov/pubmed/34367135 http://dx.doi.org/10.3389/fimmu.2021.669103

Ejemplares similares

Therapeutic antibodies under development for SARS‐CoV‐2
por: Ma, Zetong, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
por: Lei, Changhai, et al.
Publicado: (2020)

TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance
por: Fu, Wenyan, et al.
Publicado: (2021)

Engineered soluble ACE2 receptor: Responding to change with change
por: Li, Guangyao, et al.
Publicado: (2023)

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
por: Sloas, Christopher, et al.
Publicado: (2021)

Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection
por: Christodoulou, Ilias, et al.
Publicado: (2021)

The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy
por: Qian, Kewen, et al.
Publicado: (2022)

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
por: Fu, Wenyan, et al.
Publicado: (2019)

Macrophage Boolean networks in the time of SARS-CoV-2
por: de León, Ugo Avila-Ponce, et al.
Publicado: (2022)

CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro
por: Ma, Minh Tuyet, et al.
Publicado: (2021)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe?
por: Abassi, Zaid, et al.
Publicado: (2020)

Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions
por: Abdelmoaty, Mai M., et al.
Publicado: (2021)

Macrophages and γδ T cells interplay during SARS-CoV-2 variants infection
por: Atmeh, Perla Abou, et al.
Publicado: (2022)

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
por: Abdelrahman, Zeinab, et al.
Publicado: (2020)

Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
por: Guo, Yugang, et al.
Publicado: (2018)

Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer
por: Piening, Alexander, et al.
Publicado: (2022)

Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency
por: Fu, Wenyan, et al.
Publicado: (2023)

The Role of Macrophages in the Pathogenesis of SARS-CoV-2-Associated Acute Respiratory Distress Syndrome
por: Kosyreva, Anna, et al.
Publicado: (2021)

The interplay between the airway epithelium and tissue macrophages during the SARS-CoV-2 infection
por: Barreto-Duran, Emilia, et al.
Publicado: (2022)

Editorial: Screening and verification of new targets for CAR-T immunotherapy in cancer
por: Su, Yang, et al.
Publicado: (2023)

Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection
por: Liang, Yanwen, et al.
Publicado: (2020)

Macrophages and Dendritic Cells Are Not the Major Source of Pro-Inflammatory Cytokines Upon SARS-CoV-2 Infection
por: Niles, Marc A., et al.
Publicado: (2021)

Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses
por: Cao, Yingying, et al.
Publicado: (2021)

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy
por: Yang, Mingya, et al.
Publicado: (2021)

CAR T-cells for colorectal cancer immunotherapy: Ready to go?
por: Ghazi, Bouchra, et al.
Publicado: (2022)

Biomaterials promote in vivo generation and immunotherapy of CAR-T cells
por: Qin, Ya-Ting, et al.
Publicado: (2023)

Cannabidiol and SARS-CoV-2 Infection
por: Vallée, Alexandre
Publicado: (2022)

Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan
por: Chao, Chiao-Hsuan, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
por: Miao, Lele, et al.
Publicado: (2021)

Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors
por: Yu, Tao, et al.
Publicado: (2022)

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity
por: del Fresno, Carlos, et al.
Publicado: (2021)

Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection
por: Cui, Dawei, et al.
Publicado: (2021)

Immunomodulatory Drugs in the Management of SARS-CoV-2
por: Burrage, Daniel R., et al.
Publicado: (2020)

Immunity to SARS-CoV-2: Lessons Learned
por: Fergie, Jaime, et al.
Publicado: (2021)

The Spike of SARS-CoV-2: Uniqueness and Applications
por: Kumavath, Ranjith, et al.
Publicado: (2021)

SARS-CoV-2 and the host-immune response
por: Maison, David P., et al.
Publicado: (2023)

Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria
por: Eggenhuizen, Peter J., et al.
Publicado: (2022)

Therapy Targets SARS-CoV-2 Infection-Induced Cell Death
por: Zhu, Zhoujie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1lur3bhnqehq5t0lbd9f832mt9